{
    "2019-11-28": [
        [
            {
                "time": "2019-11-28",
                "original_text": "重磅！医保谈判爆出大利好，救命药最高降60%！",
                "features": {
                    "keywords": [
                        "医保谈判",
                        "降价",
                        "利好",
                        "救命药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-28",
                "original_text": "医保谈判结果公布，利好国产创新企业",
                "features": {
                    "keywords": [
                        "医保谈判",
                        "国产创新",
                        "利好"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-28",
                "original_text": "PD-1医保谈判生变：君实疑似落选，外资持续观望，恒瑞笑了？",
                "features": {
                    "keywords": [
                        "PD-1",
                        "医保谈判",
                        "君实",
                        "恒瑞",
                        "外资"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-11-28",
                "original_text": "【科新先声】2019年国家医保药品目录调整工作结束，有哪些亮点？【安信诸海滨团队】",
                "features": {
                    "keywords": [
                        "医保药品目录",
                        "调整",
                        "亮点"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-28",
                "original_text": "2019年国家医保谈判准入药品名单公布 机构建议关注创新药领域",
                "features": {
                    "keywords": [
                        "医保谈判",
                        "准入药品",
                        "创新药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-28",
                "original_text": "医保局“为民砍价”火了，降价超60%！这些A股公司“中标”，百亿“聪明钱”提前埋伏！",
                "features": {
                    "keywords": [
                        "医保局",
                        "降价",
                        "A股",
                        "中标"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-28",
                "original_text": "降价63%成为唯一进医保的PD-1 信达生物股价微跌",
                "features": {
                    "keywords": [
                        "降价",
                        "PD-1",
                        "信达生物",
                        "医保"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}